Chemotherapy Administration during Pelvic Radiation for Cervical Cancer Patients Aged ≥55 Years in the SEER-Medicare Population

por Kunos, Charles, Gibbons, Heidi, Simpkins, Fiona, Waggoner, Steven
Publicado 2008

VEGFA activates an epigenetic pathway upregulating ovarian cancer‐initiating cells

por Jang, Kibeom, Kim, Minsoon, Gilbert, Candace A, Simpkins, Fiona, Ince, Tan A, Slingerland, Joyce M
Publicado 2017

Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer

por Capo-chichi, Callinice D, Cai, Kathy Q, Simpkins, Fiona, Ganjei-Azar, Parvin, Godwin, Andrew K, Xu, Xiang-Xi
Publicado 2011

Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target

por Pierini, Stefano, Tanyi, Janos L., Simpkins, Fiona, George, Erin, Uribe-Herranz, Mireia, Drapkin, Ronny, Burger, Robert, Morgan, Mark A., Facciabene, Andrea
Publicado 2020

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis

por Cadoo, Karen, Simpkins, Fiona, Mathews, Cara, Liu, Ying L., Provencher, Diane, McCormick, Colleen, ElNaggar, Adam C., Altman, Alon D., Gilbert, Lucy, Black, Destin, Kabil, Nashwa, Bennett, James, Munley, Jiefen, Aghajanian, Carol
Publicado 2022

Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer

por Garcia‐Soto, Arlene E., McKenzie, Nathalie D., Whicker, Margaret E., Pearson, Joseph M., Jimenez, Edward A., Portelance, Lorraine, Hu, Jennifer J., Lucci, Joseph A., Qureshi, Rehman, Kossenkov, Andrew, Schwartz, Lauren, Mills, Gordon B., Maity, Amit, Lin, Lilie L., Simpkins, Fiona
Publicado 2021

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

por Bauer, Todd M., Moore, Kathleen N., Rader, Janet S., Simpkins, Fiona, Mita, Alain C., Beck, J. Thaddeus, Hart, Lowell, Chu, Quincy, Oza, Amit, Tinker, Anna V., Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David, Fu, Siqing
Publicado 2023

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

por Kim, Hyoung, Xu, Haineng, George, Erin, Hallberg, Dorothy, Kumar, Sushil, Jagannathan, Veena, Medvedev, Sergey, Kinose, Yasuto, Devins, Kyle, Verma, Priyanka, Ly, Kevin, Wang, Yifan, Greenberg, Roger A., Schwartz, Lauren, Johnson, Neil, Scharpf, Robert B., Mills, Gordon B., Zhang, Rugang, Velculescu, Victor E., Brown, Eric J., Simpkins, Fiona
Publicado 2020

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models

por Xu, Haineng, George, Erin, Kinose, Yasuto, Kim, Hyoung, Shah, Jennifer B., Peake, Jasmine D., Ferman, Benjamin, Medvedev, Sergey, Murtha, Thomas, Barger, Carter J., Devins, Kyle M., D’Andrea, Kurt, Wubbenhorst, Bradley, Schwartz, Lauren E., Hwang, Wei-Ting, Mills, Gordon B., Nathanson, Katherine L., Karpf, Adam R., Drapkin, Ronny, Brown, Eric J., Simpkins, Fiona
Publicado 2021

Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer

por Kinose, Yasuto, Xu, Haineng, Kim, Hyoung, Kumar, Sushil, Shan, Xiaoyin, George, Erin, Wang, Xiaolei, Medvedev, Sergey, Ferman, Benjamin, Gitto, Sarah B., Whicker, Margaret, D’Andrea, Kurt, Wubbenhorst, Bradley, Hallberg, Dorothy, O’Connor, Mark, Schwartz, Lauren E., Hwang, Wei-Ting, Nathanson, Katherine L, Mills, Gordon B., Velculescu, Victor E., Wang, Tian-Li, Brown, Eric J., Drapkin, Ronny, Simpkins, Fiona
Publicado 2023